Enhanced Genomics Limited
12423696
Healthy
- Current liabilities exceed current assets (-10)
Details
Compliance
Last accounts
31/12/2024
total exemption full
Next accounts due
30/09/2026
Confirmation statement
Last: 03/02/2026
Due 17/02/2027
Industry
Officers
secretary · Since 01/04/2025
director · Since 18/07/2025
DIRECTOR
BRITISH · UNITED KINGDOM · Age 33
Also on 2 other boards
Persons with Significant Control
Bgf Investment Management Limited
13-15, York Buildings, London, WC2N 6JU
Reg: 10608481 · Companies House · Private Limited Company
Notified 28/08/2025
Mnl (Parkwalk) Nominees Limited
4th Floor, 140 Aldersgate Street, London, EC1A 4HY
Notified 26/11/2025
Former PSCs
Dr Mikhail Spivakov
Ceased 05/08/2020
Dr Stefan Walter Schoenfelder
Ceased 05/08/2020
Prof Peter John Fraser
Ceased 05/08/2020
Prof Peter John Fraser
Ceased 01/04/2021
Bioqube Factory Fund I Commv
Ceased 02/09/2022
CompanyRankvs 570+ SIC 72110 peers80
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Key FinancialsYear ending 31/12/2024
Net Worth
£3.7M
Balance sheet strength
Cash
£1.9M
Cash in the bank
Net Current Assets
£3.1M
Working capital
Current Assets
£3.4M
Current Liabilities
£347k
Fixed Assets
£619k
Debtors
£1.5M
Balance Sheet
EstimatesDerived
| Year | Current Ratio | Implied Profit |
|---|---|---|
| 2024 | 9.87 | -£3.4M |
| 2023 | 18.84 | -£2.7M |
| 2022 | 54.30 | +£8.8M |
| 2021 | 15.93 | — |
Derived from filed accounts. Not audited figures.